Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.

Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F; KALM-1 Trial Investigators.

N Engl J Med. 2020 Jan 16;382(3):222-232. doi: 10.1056/NEJMoa1912770. Epub 2019 Nov 8.

PMID:
31702883
2.

Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain.

Arendt-Nielsen L, Olesen AE, Staahl C, Menzaghi F, Kell S, Wong GY, Drewes AM.

Anesthesiology. 2009 Sep;111(3):616-24. doi: 10.1097/ALN.0b013e3181af6356.

PMID:
19672186
3.

Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors.

Vanderah TW, Largent-Milnes T, Lai J, Porreca F, Houghten RA, Menzaghi F, Wisniewski K, Stalewski J, Sueiras-Diaz J, Galyean R, Schteingart C, Junien JL, Trojnar J, Rivière PJ.

Eur J Pharmacol. 2008 Mar 31;583(1):62-72. doi: 10.1016/j.ejphar.2008.01.011. Epub 2008 Jan 24.

PMID:
18282565
4.

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.

Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, Al-Shamma H, Smith B, Chalmers D, Behan D.

J Pharmacol Exp Ther. 2008 May;325(2):577-87. doi: 10.1124/jpet.107.133348. Epub 2008 Feb 5.

PMID:
18252809
5.

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.

Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Dosa PI, Covel JA, Ren A, Webb RR, Beeley NR, Martin M, Morgan M, Espitia S, Saldana HR, Bjenning C, Whelan KT, Grottick AJ, Menzaghi F, Thomsen WJ.

J Med Chem. 2008 Jan 24;51(2):305-13. Epub 2007 Dec 21.

PMID:
18095642
6.

Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.

Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Thomsen WJ, Saldana HR, Whelan KT, Menzaghi F, Webb RR, Beeley NR.

Bioorg Med Chem Lett. 2005 Mar 1;15(5):1467-70.

PMID:
15713408
7.

Sites of neocortical reorganization critical for remote spatial memory.

Maviel T, Durkin TP, Menzaghi F, Bontempi B.

Science. 2004 Jul 2;305(5680):96-9. Erratum in: Science. 2004 Aug 13;305(5686):946.

8.

Pharmacological characterization of SIB-1663, a conformationally rigid analog of nicotine.

Rao TS, Sacaan AI, Menzaghi FM, Reid RT, Adams PB, Correa LD, Whelan KT, Vernier JM.

Brain Res. 2004 Apr 2;1003(1-2):42-53.

PMID:
15019562
9.

Constitutively activated G protein-coupled receptors: a novel approach to CNS drug discovery.

Menzaghi F, Behan DP, Chalmers DT.

Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):105-21. Review.

PMID:
12769637
11.
12.

Selective immunolesioning of the basal forebrain cholinergic neurons in rats: effect on attention using the 5-choice serial reaction time task.

Risbrough V, Bontempi B, Menzaghi F.

Psychopharmacology (Berl). 2002 Oct;164(1):71-81. Epub 2002 Aug 9.

PMID:
12373421
15.
17.
18.

Reduced cerebrospinal fluid levels of alpha-secretase-cleaved amyloid precursor protein in aged rats: correlation with spatial memory deficits.

Anderson JJ, Holtz G, Baskin PP, Wang R, Mazzarelli L, Wagner SL, Menzaghi F.

Neuroscience. 1999;93(4):1409-20.

PMID:
10501466
19.

Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys.

Schneider JS, Tinker JP, Van Velson M, Menzaghi F, Lloyd GK.

J Pharmacol Exp Ther. 1999 Aug;290(2):731-9.

PMID:
10411585
20.

4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors.

Vernier JM, El-Abdellaoui H, Holsenback H, Cosford ND, Bleicher L, Barker G, Bontempi B, Chavez-Noriega L, Menzaghi F, Rao TS, Reid R, Sacaan AI, Suto C, Washburn M, Lloyd GK, McDonald IA.

J Med Chem. 1999 May 20;42(10):1684-6. No abstract available.

PMID:
10346920
21.

Conformationally restricted analogues of nicotine and anabasine.

Vernier JM, Holsenback H, Cosford ND, Whitten JP, Menzaghi F, Reid R, Rao TS, Sacaan AI, Lloyd GK, Suto CM, Chavez-Noriega LE, Washburn MS, Urrutia A, McDonald IA.

Bioorg Med Chem Lett. 1998 Aug 18;8(16):2173-8.

PMID:
9873508
22.

Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.

Schneider JS, Pope-Coleman A, Van Velson M, Menzaghi F, Lloyd GK.

Mov Disord. 1998 Jul;13(4):637-42.

PMID:
9686767
23.

The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents.

Lloyd GK, Menzaghi F, Bontempi B, Suto C, Siegel R, Akong M, Stauderman K, Velicelebi G, Johnson E, Harpold MM, Rao TS, Sacaan AI, Chavez-Noriega LE, Washburn MS, Vernier JM, Cosford ND, McDonald LA.

Life Sci. 1998;62(17-18):1601-6. Review.

PMID:
9585143
24.

Neuropeptide Y-induced feeding and its control.

Heinrichs SC, Menzaghi F, Koob GF.

Vitam Horm. 1998;54:51-66. Review. No abstract available.

PMID:
9529973
25.
26.

Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.

Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK.

J Pharmacol Exp Ther. 1997 Jan;280(1):393-401.

PMID:
8996220
27.

Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats.

Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK.

J Pharmacol Exp Ther. 1997 Jan;280(1):384-92.

PMID:
8996219
28.

(S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors.

Cosford ND, Bleicher L, Herbaut A, McCallum JS, Vernier JM, Dawson H, Whitten JP, Adams P, Chavez-Noriega L, Correa LD, Crona JH, Mahaffy LS, Menzaghi F, Rao TS, Reid R, Sacaan AI, Santori E, Stauderman KA, Whelan K, Lloyd GK, McDonald IA.

J Med Chem. 1996 Aug 16;39(17):3235-7. No abstract available.

PMID:
8765504
29.

IRI-514, a synthetic peptide analogue of thymopentin, reduces the behavioral response to social stress in rats.

Menzaghi F, Heinrichs SC, Vargas-Cortes M, Goldstein G, Koob GF.

Physiol Behav. 1996 Aug;60(2):397-401.

PMID:
8840897
30.

Epibatidine: a nicotinic acetylcholine receptor agonist releases monoaminergic neurotransmitters: in vitro and in vivo evidence in rats.

Sacaan AI, Menzaghi F, Dunlop JL, Correa LD, Whelan KT, Lloyd GK.

J Pharmacol Exp Ther. 1996 Feb;276(2):509-15.

PMID:
8632316
31.
32.

The role of CRF in behavioral aspects of stress.

Heinrichs SC, Menzaghi F, Merlo Pich E, Britton KT, Koob GF.

Ann N Y Acad Sci. 1995 Dec 29;771:92-104. Review.

PMID:
8597448
33.

Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal.

Heinrichs SC, Menzaghi F, Schulteis G, Koob GF, Stinus L.

Behav Pharmacol. 1995 Jan;6(1):74-80.

PMID:
11224314
34.

Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity.

Heinrichs SC, Menzaghi F, Pich EM, Baldwin HA, Rassnick S, Britton KT, Koob GF.

Neuropsychopharmacology. 1994 Nov;11(3):179-86.

35.

The role of corticotropin-releasing factor in the anxiogenic effects of ethanol withdrawal.

Menzaghi F, Rassnick S, Heinrichs S, Baldwin H, Pich EM, Weiss F, Koob GF.

Ann N Y Acad Sci. 1994 Oct 31;739:176-84. Review.

PMID:
7832471
36.

Characterization of a novel and potent corticotropin-releasing factor antagonist in rats.

Menzaghi F, Howard RL, Heinrichs SC, Vale W, Rivier J, Koob GF.

J Pharmacol Exp Ther. 1994 May;269(2):564-72.

PMID:
8182523
37.

Involvement of hypothalamic corticotropin-releasing factor neurons in behavioral responses to novelty in rats.

Menzaghi F, Heinrichs SC, Merlo-Pich E, Tilders FJ, Koob GF.

Neurosci Lett. 1994 Feb 28;168(1-2):139-42.

PMID:
8028766
38.

The role of limbic and hypothalamic corticotropin-releasing factor in behavioral responses to stress.

Menzaghi F, Heinrichs SC, Pich EM, Weiss F, Koob GF.

Ann N Y Acad Sci. 1993 Oct 29;697:142-54. Review.

PMID:
8257007
39.

Corticotropin-releasing factor release from the mediobasal hypothalamus of the rat as measured by microdialysis.

Pich EM, Koob GF, Heilig M, Menzaghi F, Vale W, Weiss F.

Neuroscience. 1993 Aug;55(3):695-707.

PMID:
8413932
40.
41.

Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects.

Heilig M, McLeod S, Brot M, Heinrichs SC, Menzaghi F, Koob GF, Britton KT.

Neuropsychopharmacology. 1993 Jun;8(4):357-63.

42.

Corticotropin-releasing factor in the paraventricular nucleus modulates feeding induced by neuropeptide Y.

Heinrichs SC, Menzaghi F, Pich EM, Hauger RL, Koob GF.

Brain Res. 1993 May 14;611(1):18-24.

PMID:
8518948
43.

The role of corticotropin-releasing factor in behavioural responses to stress.

Koob GF, Heinrichs SC, Pich EM, Menzaghi F, Baldwin H, Miczek K, Britton KT.

Ciba Found Symp. 1993;172:277-89; discussion 290-5. Review.

PMID:
8491090
44.

Long-term reduction of vasopressin excretion induced by the central injection of an immunoconjugate (antibody to vasopressin linked to ricin A chain).

Burlet A, Chapleur-Chateau M, Haumont-Pellegri B, Jansen F, Menzaghi F, Fernette B, Nicolas JP, Burlet C.

Neuroscience. 1992 Oct;50(4):965-73.

PMID:
1448207
45.

Endogenous corticotropin-releasing factor modulates feeding induced by neuropeptide Y or a tail-pinch stressor.

Heinrichs SC, Cole BJ, Pich EM, Menzaghi F, Koob GF, Hauger RL.

Peptides. 1992 Sep-Oct;13(5):879-84.

PMID:
1480513
46.

Alteration of pituitary-adrenal responses to adrenalectomy by the immunological targeting of CRF neurons.

Menzaghi F, Burlet A, Chapleur M, Nicolas JP, Burlet C.

Neurosci Lett. 1992 Jan 20;135(1):49-52.

PMID:
1311823
47.

Long-term inhibition of stress-induced adrenocorticotropin release by intracerebral administration of a monoclonal antibody to rat corticotropin-releasing factor together with ricin a chain and monensin.

Menzaghi F, Burlet A, Oers JW, Tilders FJ, Nicolas JP, Burlet C.

J Neuroendocrinol. 1991 Oct 1;3(5):469-75. doi: 10.1111/j.1365-2826.1991.tb00305.x.

PMID:
19215494
48.

Uptake of a monoclonal antibody to corticotropin-releasing factor (CRF) into rat hypothalamic neurons.

Burlet AJ, Menzaghi F, Tilders FJ, van Oers JW, Nicolas JP, Burlet CR.

Brain Res. 1990 May 28;517(1-2):283-93.

PMID:
2375997
49.

Antibodies to neuropeptides: biological effects and mechanisms of action.

Tilders FJ, van Oers JW, White A, Menzaghi F, Burlet A.

Adv Exp Med Biol. 1990;274:135-46. Review. No abstract available.

PMID:
2239423

Supplemental Content

Loading ...
Support Center